Merck’s investigational pneumococcal vaccine shows promise in older adults

28 Jul 2023
www.pmlive.com
Clinical ResultVaccinePhase 3
Merck & Co – known as MSD outside the US and Canada – has shared positive results from two late-stage trials evaluating its investigational 21-valent pneumococcal conjugate vaccine in adults.
Merck & Coal disease iMSDhe name for any infection caused by bacteria called Streptococcus pneumoniae and is considered a “major public health problem worldwide” by the World Health Organization.
Pneumococcal disease100 different types oinfectionoccal bacteria, which can affect adults differently than children. Highly aggressive strains threaten to put more people at risk for invasive pneumococcal illnesses, Merck reports, and older adults are among those most vulnerable to serious infection.
Merck’s candidate, V116, is specifically designed to address the strains that represent adult pneumococcal disease, including eight unique strains which account for approximately 30% of adult disease.Merckinfection
Merckproved, V116 wV116 be the first pneumococcal conjugate vaccine specifically designed for pneumococcal diseaseion, according to the company.
Results from V116phase 3 STRIDE-3 tripneumococcal conjugate vaccineV116 in vaccine-naïve adults, demonstrated statistically significant immune responses compared with Pfizer's 20-valent vaccine, Prevnar 20, for strains common to both vaccines as well as those unique to V116.
Additionally, results from the phase 3 STRIDE-6 trial demonstrated V116 V116 was immunogenic for all 21 pneumococcal strains in the vaccine among adults who had receivPfizerneumococcal vaccine at least one year prior to the study.
V116 had a safety profile comparable to the comparator in both studies, V116k said, adding that the results will now be shared with the scientific community and will supporpneumococcal vaccineapplications.
V116liav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories, said: “Despite the availability of current pneumococcal conjugate vaccines, many adults remain vulnerable to pneumococcal disease, especially those who are older.
“These results support the potential for V116 to become an important new preventative option for adulMerck Research Laboratoriesumococcal vaccination status, by expanding copneumococcal conjugate vaccineses not currently included in any lipneumococcal disease
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.